

**Study of Prolactin, Ferritin & Vitamin D as
Immunomodulatory Markers in Patients
with Rheumatoid Arthritis**

*Thesis submitted for partial fulfillment of Master Degree in
Endocrinology*

By

Manal Mohammed Abdel Hamid Hassan

M.B., B.CH

Supervised by

Dr. Mohammad Hesham El-Gayar

*Professor of Internal Medicine and Endocrinology
Faculty of Medicine – Ain Shams University*

Dr. Salwa Seddik Hosny

*Assistant Prof. of Internal Medicine & Endocrinology
Faculty of Medicine – Ain Shams University*

Dr. Manal Mohammad Abu Shady

*Assistant Prof. of Internal Medicine & Endocrinology
Faculty of Medicine – Ain Shams University*

**Faculty of Medicine
Ain Shams University
Cairo-Egypt**

2010

Acknowledgement

*Thanks first and last to **ALLAH** for His guidance, support and care in every step in our lives.*

*It is a great pleasure to acknowledge my deepest gratitude to **DR.MOHAMMAD HESHAM EL-GAYAR**, Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University, for his unlimited help, encouragement, supervision and support so that this work have been accomplished.*

*I have the greatest pleasure to express my gratitude to **DR.SALWA SEDDIK HOSNY**, Assistant Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University, for her supervision, guidance and help.*

*In addition, I have the greatest honor to express my deep thanks to **DR.MANAL MOHAMMAD ABU SHADY**, Assistant Professor of Internal Medicine and Endocrinology, Faculty of Medicine, Ain Shams University for her supervision, endless support, encouragement and great assistance.*

*Special thanks, gratitude and gratefulness to **DR.IHAB SHEHAD HABIL**, Assistant Professor of Community, Enviromental and Occupational Medicine, Faculty of Medicine, Ain Shams University for perfectly performing the*

statistical part of the work.

*Also, special thanks, gratitude and gratefulness to **DR.MAGDY ABBAS** and **DR.SAMIA EL-TOHAMY**, Assistant Consultants of Biochemistry in Ain Shams University Hospitals for perfectly performing the practical part of the work.*

*Lastly, I have to express my appreciation to all my family and specially my husband **DR.TAMER YEHIA**, as without their support and help this work would have not been fulfilled.*

Thesis Protocol

Introduction:

Rheumatoid arthritis (R.A) is a chronic autoimmune inflammatory disease characterized by persistent joint synovial tissue inflammation (**Ruddy *et al*; 2005**)^a. The etiology of R.A is not fully understood. Evidence points to a complex interplay between environmental and genetic factors (**Goldring,2000**). Multiple cytokines, interleukins (ILs) and growth factors are released, causing further joint destruction and development of systemic complications (**Ruddy *et al*; 2005**)^a.

Prolactin (secreted by lactotrophs in anterior pituitary) has immunomodulatory as well as lactogenic effects. Prolactin is made in extrapituitary tissues including T-lymphocytes, B-lymphocytes and human chorion. Prolactin produced by T-lymphocytes is believed to have autocrine and paracrine functions. The physiologically-significant lymphocyte PRL, particularly in individuals with autoimmune diseases, has been debated (**Chuang and Molitch,2007**).

Serum ferritin protein is an acute phase reactant elevated in any inflammatory state e.g infection, R.A, hepatitis and cancer (**Victor Herbert *et al*,1997**). Ferritin levels in synovial fluid not in serum are significantly elevated in R.A more than in osteoarthritis (O.A) (**Kumon *et al*,1999**).

There is inverse correlation between serum 1,25(OH)₂ D₃ and disease activity in patients with R.A.

The decrease of active vitamin D levels in those patients may contribute to negative calcium balance and inhibition of bone formation (**Oelzner *et al.*,1998**).

Hypercalcaemia is associated with high disease activity and may contribute to suppression of PTH (parathormone) secretion and vitamin D hormone synthesis. High levels of ionized calcium may be a reflection of disease-activity related systemic bone loss (**Oelzner *et al.*, 2006**).

Preventive treatment with vitamin D (for hypercalcaemia) or therapy for HPRL with dopamine agonists, may be considered in certain cases (**Orbach *et al.*,2007**). A clinical benefit using bromocriptine (a dopamine agonist) in patients with various inflammatory arthritides (including R.A, Reiter's syndrome and SLE) has been described as well as cabergoline. In contrast, a recent study of prolactin inhibitor quinagolide in nine R.A patients did not show any significant benefit. So, prolactin levels should be checked in patients with persistently active R.A despite treatment. Further studies are required to delineate whether prolactin inhibitors provide clinical benefit additional to that of conventional disease-modifying agents in R.A patients with normal prolactin levels (**Erb *et al.*,2001**).

Aim of the work:

The aim of present study is to assess the relation of prolactin, ferritin and vitamin D levels as immunomodulatory markers in patients with rheumatoid arthritis.

Subjects and Methods:

Study will be conducted on 50 female subjects: 20 healthy controls and 30 patients with RA selected from Ain-Shams University Hospital. Patients will be subdivided into two groups:

-Group A: 15 (fifteen) patients with active R.A.

-Group B: 15 (fifteen) patients in remission of rheumatoid activity.

Inclusion Criteria

Diagnosis of patients typically is made when four of seven qualifying criteria established by American Rheumatism Association are met (**Saraux *et al*,2001**). These qualifying criteria are:

1-Morning Stiffness: in or around the affected joints for at least one hour after initiating movement.

2-Arthritis of three or more joint areas: e.g wrist, PIP, MCP, MTP, elbow, knee, ankle.

3-Arthritis of the hand: particularly involvement of PIP, MCP joints, or wrist joints.

4-Symmetric arthritis.

5-Rheumatoid nodules.

6-Serum rheumatoid factor positive: 95% or more.

7-Radiographic changes: typical changes of erosions or loss of bone density adjacent to affected joints.

- Diagnostic tests (recommended by American College of Rheumatology Subcommittee on R.A): **(Ruddy *et al*; 2005)**

1-C-reactive protein: typically increased to more than 0.7 picograms per ml.

2-Erythrocyte sedimentation rate: often increased to more than 30 mm per hour.

3-Hemoglobin/hematocrit: slightly decreased “i.e. normochromic anemia”, may be normocytic or microcytic.

4-Liver function: normal or slightly elevated alkaline phosphatase (ALP).

5-Platelets: usually increased.

6-Radiographic findings: may be normal or show osteopenia or erosions near joint spaces.

7-Rheumatoid factor: positive in approximately 70% of patients with R.A.

8-White blood count: may be increased.

Exclusion Criteria

Patients with any cause of hyperprolactinaemia as: prolactinoma, pregnancy, lactation, hypothyroidism, emotional stress, drugs e.g Motilium, Primperan, Cimetidine.

History of intake of vitamin D and calcium within one month.

All cases enrolled into study will be submitted to:

- 1-Full medical history.
- 2-Full clinical examination: pulse, blood pressure, weight, careful joint examination, complete drug history.
- 3-Laboratory investigations:
Routine investigations: ESR, rheumatoid factor, CBC.
- 4-Prolactin: measured using ELISA technique.
- 5-Ferritin: measured using ELISA technique.
- 6-Vitamin D: measured using ELISA technique.

References :

- **Chuang E and Molitch M.** Prolactin and autoimmune diseases in humans. *A CTA B IOMED* 2007;78;Suppl 1:255-261.
- **Erb N , Pace AV, Delamere JP , et al.** Control of unremitting rheumatoid arthritis by the prolactin antagonist cabergoline. *Rheumatology* 2001;40:237-239.
- ^a- **Firestein GS.** Etiology and pathogenesis of rheumatoid arthritis. In: **Ruddy S, Harris ED, Sledge CB, et al.** *Kelley's textbook of rheumatology.7th ed.* Philadelphia:W.B.Saunders,2005:996-1042.
- ^b- **Harris ED.** Clinical features of rheumatoid arthritis. In: **Ruddy S, Harris ED, Sledge CB, et al.** *Kelley's textbook of rheumatology.7th ed.* Philadelphia:W.B.Saunders,2005:1043-78.
- **Herbert V, Shaw S, Jayatilleke E, et al.** Serum Ferritin Iron, a New Test, Measures Human Body Stores Unconfounded by Inflammation. *Stem Cells*,Vol.15,No.4,291-296, July 1997.
- **Kumon Y, Suehiro T, Nishiya K, et al.** Ferritin correlates with C-reactive protein and acute phase serum amyloid A in synovial fluid, but not in serum. *Amyloid*.1999 Jun;6(2):130-5.
- **Oelzner P, Lehmann G , Eidner T, et al.** Hypercalcemia in rheumatoid arthritis: relationship with disease

activity and bone metabolism. *Rheumatology international* ISSN 0172-8172.2006,Vol.26,No. 10,pp.908-915.

- **Oelzner P, Muller A, Deschner F, et al.** Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. *Calcif Tissue Int.*1998 Mar;62(3):193-8.
- **Orbach H, Zandman-Goddard G, Amital H, et al.** Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases.*Ann N Y Acad sci* 2007 Aug;1109:385-400.
- **Saraux A, Berthelot M, Chales G, et al.** Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. *Arthritis Rheum* 2001;44:2485-91.

LIST OF ABBREVIATIONS

ACPA	Antibodies to Citrullinated Peptides or Anti-Citrullinated Protein antibodies.
ACD	Anemia of chronic disease
ACR	American College of Rheumatology
ACRSRA	American College of Rheumatology Subcommittee on Rheumatoid Arthritis.
ADCC	Antibody Dependent Cell-mediated Cytotoxicity.
ALP	Alkaline phosphatase.
ANA	Antinuclear antibody.
Anti-CCP	Anti-cyclic citrullinated peptide.
Anti-ds DNA	Anti-double-stranded DNA.
Anti-MCV	Antibodies against mutated citrullinated vimentin.
APCs	Antigen-presenting cells.
APRs	Acute-phase reactants.

b/min.	Beat/minute.
CBC	Complete blood count.
CBL	Casitas B-Lineage Lymphoma.
CD4+	T _H (helper) cells.
CDAI	Clinical Disease Activity Index.
cDNA	Complementary DNA.
CNS	Central nervous system.
CRP	C-reactive protein.
D2	Ergocalciferol.
D3	Cholecalciferol.
DA	Dopamine.
DAS	Disease Activity Score.
DCH	Dehydrocholesterol.
dm	Dermatomyositis.
DMARDs	Disease-modifying anti-rheumatic drugs.
DNA	Deoxyribonucleic acid.

EBV	Epstein-Barr virus.
EDTA	Ethylene Diamine tetra-acetate.
ELISA	Enzyme-linked immunosorbent assay.
ESR	Erythrocyte sedimentation rate.
EULAR	European League Against Rheumatism.
Fc	Fragment, crystallizable.
FDA	Food and Drug Administration.
GABA	Gamma-amino butyric acid.
GC	Germinal center.
HAQ	Health Assessment Questionnaire.
Hb	Hemoglobin.
HHV-6	Human Herpes virus-6.
HLA	Human leucocytic antigen.
Hp	Haptoglobin.
HPRL	Hyperprolactinemia.

IDA	Iron-deficiency anemia.
IFN-γ	Interferon-gamma.
Ig	Immunoglobulin.
IL	Interleukin.
IU	International unit.
KDa	Kilodalton.
Kg	Kilogram.
L	Litre.
MCHC	Mean corpuscular hemoglobin concentration.
MCP	Metacarpophalangeal.
MCV	Mean corpuscular volume.
MDA	Minimal Disease Activity.
MHC	Major Histocompatibility Complex.
mL	millilitre.
MRI	Magnetic resonance imaging.

mRNA	messenger RNA.
MS	Multiple sclerosis.
MTP	Metatarsophalangeal.
MTX	Methotrexate.
mU	milli-international unit.
NAB	Neutralizing antibodies.
NF- B	Nuclear factor kappa-light-chain-enhancer of activated B cells.
ng	nanogram.
NK	Natural killer.
nmol	nanomol
NSAIDs	Non-steroidal anti-inflammatory drugs.
NT	Neurotensin.
O.A	Osteoarthritis.
OT	Oxytocin.